The Conversation (0)
Anchiano Therapeutics Announces Pricing of $30.5 Million Initial Public Offering
Feb. 12, 2019 08:40AM PST
Biotech Investing
Anchiano Therapeutics (NASDAQ:ANCN) has announced it has priced its initial public offering of 2.65 million shares at a price of US$11.50 each. As quoted in the press release: The ADSs are expected to begin trading on the Nasdaq Capital Market (“Nasdaq”) under the symbol “ANCN” on February 12, 2019, and the offering is expected to …
Anchiano Therapeutics (NASDAQ:ANCN) has announced it has priced its initial public offering of 2.65 million shares at a price of US$11.50 each.
As quoted in the press release:
The ADSs are expected to begin trading on the Nasdaq Capital Market (“Nasdaq”) under the symbol “ANCN” on February 12, 2019, and the offering is expected to close on or about February 14, 2019.
The underwriters have been granted a 30-day option to purchase up to an additional 397,826 ADSs offered by Anchiano to cover over-allotments, if any.
In the offering, Oppenheimer & Co. Inc. is acting as the sole book-running manager, Ladenburg Thalmann is acting as lead manager and LifeSci Capital LLC is acting as co-manager.
The offering is being made only by means of a prospectus, copies of which can be obtained from Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad St., 26th Floor, New York, NY 10004, by telephone at (212) 667-8055 or by email at EquityProspectus@opco.com.